Skip to content
Log in
Sponsored Artificial Intelligence: A Modern Approach, Global Edition Artificial Intelligence: A Modern Approach, Global Edition
Open access

Multivalent Anti-ACE2 Nanobodies Confer Broad Pan-Sarbecovirus Protection

A. Bakasis Rachel Patejak Peter C. Fridy J. Jenkins Miranda Aldis Viren A. Baharani Lakshmi Sriram Kelley R. Molloy Brian T. Chait Michael P. Rout F. Cross P. Bieniasz T. Hatziioannou
Sep 2026 · bioRxiv · 0 citations · 1 references
Biology

TL;DR

A nanobody discovery pipeline incorporating competition-based yeast surface display assays is optimized to isolate single-chain variable heavy chain-only antibody domains (VHHs or nanobodies) that bind human ACE2 and inhibit SARS-CoV-2 entry, showcasing their potential as broadly acting receptor-targeted biologics against pandemic-threat viruses.

DOI Semantic Scholar
Read PDF

Similar papers

Open access Aug 2026

Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects

It is demonstrated that nanobodies targeting the PLpro/ISG15 interface can achieve synergistic antiviral and immunomodulatory effects, providing a proof-of-concept for a novel therapeutic approach to combat SARS-CoV-2 and potentially other emerging coronaviruses.

Guo-Long Liu, Jian-Tao Chen, Fang Wu et al. · 0 citations
#protein folding Aug 2026

Oligomerized receptor binding domain blocks pan-sarbecovirus infection via enhanced avidity to host receptor.

HRBD demonstrated potent and broad-spectrum inhibition against Pangolin-CoV, SARS-CoV, SARS-CoV, SARS-CoV-2, and its variants, lowering the half-maximal inhibitory concentration (IC50) by approximately 1000-fold compared to the monomeric RBD.

Jintao Zou, Lingyu Su, Jian-Sheng Lu et al. · 0 citations
Open access Sep 2026

AI-guided epitope engineering of a SARS-CoV-2 spike antigen for broad sarbecovirus neutralization

The rapid evolution of SARS-CoV-2 and the ongoing risk of zoonotic spillover highlight the need for vaccines that provide broad protection beyond strain-specific immunity. Here, we present a structure-guided, AI-enabled strategy for rational antigen design that enhances cross-reactive B-cell epitope recognition across...

A. Odainic, Ioannis Vardaxis, M. Ferraz et al. · 0 citations
Open access Jan 2026

A bireporter recombinant SARS-CoV-2 Omicron BA.5 for in vitro and in vivo studies

ABSTRACT The continuous emergence of variants of concern (VoCs) represents a significant challenge to effectively control severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Although FDA-approved vaccines and antivirals have been successfully developed and implemented for the prophylactic and therapeutic inte...

Esteban M. Castro, Ramya S. Barre, C. Ye et al. · 0 citations
Open access Aug 2026

Nanobodies against the S2 region of the spike protein potently neutralize SARS-CoV-2 viruses and show resistance to viral immune escape

The results show the value of nanobody technology for identifying novel neutralising epitopes in the S2 region of beta-coronaviruses with potential for the development of new selective anti-viral agents.

John D. Clarke, Luke M. Jones, Imogen I. H. Buckle et al. · 0 citations
Open access Sep 2026

Dissociation kinetics and avidity gate SARS-CoV-2 neutralization by HR2 stem helix antibodies

It is shown that plasma IgG reactivity to this region remains rare, even after repeated antigen exposure, and kinetic and avidity constraints governing neutralization at the HR2 stem helix and position hr2.016 as a resilient therapeutic candidate.

Virginia Crivelli, Concetta Guerra, M. Abernathy et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.